Immusoft is the world leader in the development of B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our approach, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response...
Total raised: $30.59M
Founded date: 2009
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors |
| 25.09.2020 | - | $4.5M | - |
| 04.01.2019 | Series B | $20M | - |
| 05.01.2018 | Series B | $3M | - |
| 11.11.2016 | - | $2.74M | - |
| 21.04.2012 | Grant | $350K | - |
Mentions in press and media 19
| Date | Title | Description |
| 29.01.2023 | Immusoft Receives $8M in Funding from the California Institute for Regenerative Medicine | Immusoft of CA, a San Francisco, CA-based wholly owned subsidiary of Immusoft Corporation, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, raised $8M in funding from Californ... |
| 01.09.2022 | Seattle biotech company is the first to receive approval to test B cell gene therapy in humans | Immusoft’s steps to delivering a treatment using engineered B cells. (Screen grab from Immusoft’s website) Seattle biotech startup Immusoft has received approval to begin clinical trials of its novel strategy for treating genetic disease, t... |
| 29.11.2021 | Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM) | Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has aw... |
| 14.10.2021 | Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M | Immusoft CEO Sean Ainsworth. (Immusoft Photo) Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 mill... |
| 25.09.2020 | Seattle gene therapy biotech startup Immusoft raises $4.5M | Seattle-based biotech startup Immusoft raised another $4.5 million and landed a $467,000 NIH grant to help further development of its drugs that treat genetic diseases. Founded in 2009, Immusoft develops immune cell technology that uses blo... |
| 04.01.2019 | Seattle biotech startup raises $20M to develop gene therapy technology | Immusoft CEO Sean Ainsworth. (Immusoft Photo) Seattle-based biotech startup Immusoft this week closed a $20 million Series B venture capital round that will fuel development of its gene therapy technology. Founded in 2009, Immusoft develops... |
| 04.01.2019 | Seattle Startup Funding News: Immusoft, TurboPatent, VYRTY & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Catch up on funding news in the Seattle area’s early-stage business ecosystem from late December and early January: —Immusoft, which is developing technology to genetically re... |
| 04.01.2019 | Top startup news for today, Friday, January 4, 2019 | Good morning! Here are some of the top technology startup news stories for today, Friday, January 4, 2019. Verily Life Sciences, an Alphabet spin-off, just raised a $1 billion investment. Verily Life Sciences (formerly known as Google Life... |
| 04.01.2019 | Immusoft Raises $20M in Series B Financing | Immusoft Corporation, a Seattle-Wash.-based cell therapy company, held the final closing in its $20m Series B financing. Backers included Breakout Ventures, Alexandria Venture Investments, RBV Capital, DEFTA Partners, and Mesa Verde Venture... |
| 03.01.2019 | Immusoft Receives $20M Series B Round | SEATTLE, WA, Immusoft, a cell therapy company, announced today it has held the final closing in its $20 million oversubscribed Series B financing. >> Click here for more funding data on Immusoft >> To export Immusoft funding... |
Show more